Filing Details

Accession Number:
0001181431-14-002327
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-14 13:28:22
Reporting Period:
2014-01-10
Filing Date:
2014-01-14
Accepted Time:
2014-01-14 13:28:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
819050 Vical Inc VICL Biological Products, (No Disgnostic Substances) (2836) 930948554
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1594604 Igor Bilinsky 10390 Pacific Center Court
San Diego CA 92121
Senior Vp, Corporate Dev't No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock $.01 Par Value Acquisiton 2014-01-10 90,000 $1.42 145,692 No 4 P Direct
Common Stock $.01 Par Value Disposition 2014-01-11 1,419 $1.42 144,273 No 4 F Direct
Common Stock $.01 Par Value Disposition 2014-01-13 305 $1.34 143,968 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 F Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nonstatutory Stock Option (right to buy) Acquisiton 2014-01-10 135,000 $0.00 135,000 $1.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
540,826 2015-01-10 2024-01-09 No 4 A Direct
Footnotes
  1. Shares were acquired pursuant to a restricted stock grant and generally vest one-third on the first anniversary of the grant, with the remainder vesting quarterly over the remaining two years.
  2. Represents shares withheld for taxes upon the release of restricted stock granted on January 11, 2013.
  3. Represents shares withheld for taxes upon the release of restricted stock granted on January 13, 2012.
  4. This balance includes 139,171 of unvested restricted stock units.
  5. The right to exercise the above stock option generally vests one-third on the first anniversary of the grant, with the remaining rights vesting quarterly over the remaining two years.